select a format

Single User License
USD 250 INR 16030
Site License
USD 500 INR 32060
Corporate User License
USD 750 INR 48090

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Momenta Pharmaceuticals Inc (MNTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Momenta Pharmaceuticals Inc (MNTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH57624D
  • |
  • Pages: 44
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company's products include Glatopa (glatiramer acetate injection, a fully substitutable generic equivalent of daily Copaxone 20 mg/mL for the treatment of relapsing-remitting multiple sclerosis (RRMS); and Enoxaparin Sodium Injection which is a generic version of Lovenox to prevent and treat deep vein thrombosis (DVT). Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc (MNTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 10

Momenta Pharma To Acquire Sialic Switch Assets Of Virdante Pharma 11

Partnerships 12

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12

Baxter International Enters Into Co-Development Agreement With Momenta Pharma For Biologics 13

Licensing Agreements 14

CSL to Enter into Licensing Agreement with Momenta Pharma 14

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 15

Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 17

Equity Offering 18

Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 18

Momenta Pharma Raises USD158 Million Public Offering of Shares 18

Momenta Pharmaceuticals Inc-Key Competitors 21

Key Employees 22

Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 24

Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 27

Nov 02, 2016: Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results 30

Aug 04, 2016: Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results 32

May 03, 2016: Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results 34

Feb 18, 2016: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results 36

Corporate Communications 38

Nov 02, 2016: Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer 38

Sep 23, 2016: Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors 39

Jun 23, 2016: Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors 40

Mar 09, 2016: Momenta Pharmaceuticals Appoints Jose-Carlos Gutierrez-Ramos, Ph.D. to Board of Directors 41

Government and Public Interest 42

Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 42

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Momenta Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 10

Momenta Pharma To Acquire Sialic Switch Assets Of Virdante Pharma 11

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12

Baxter International Enters Into Co-Development Agreement With Momenta Pharma For Biologics 13

CSL to Enter into Licensing Agreement with Momenta Pharma 14

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 15

Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 17

Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 18

Momenta Pharma Raises USD158 Million Public Offering of Shares 18

Momenta Pharmaceuticals Inc, Key Competitors 21

Momenta Pharmaceuticals Inc, Key Employees 22

Momenta Pharmaceuticals Inc, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Momenta Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com